How to Combat Gram-Negative Bacteria Using Antimicrobial Peptides: A Challenge or an Unattainable Goal?

Abstract

Antimicrobial peptides (AMPs) represent a promising and effective alternative for combating pathogens, having some advantages compared to conventional antibiotics. However, AMPs must also contend with complex and specialised Gram-negative bacteria envelops. The variety of lipopolysaccharide and phospholipid composition in Gram-negative bacteria strains and species are decisive characteristics regarding their susceptibility or resistance to AMPs. Such biological and structural barriers have created delays in tuning AMPs to deal with Gram-negative bacteria. This becomes even more acute because little is known about the interaction AMP–Gram-negative bacteria and/or AMPs’ physicochemical characteristics, which could lead to obtaining selective molecules against Gram-negative bacteria. As a consequence, available AMPs usually have highly associated haemolytic and/or cytotoxic activity. Only one AMP has so far been FDA approved and another two are currently in clinical trials against Gram-negative bacteria. Such a pessimistic panorama suggests that efforts should be concentrated on the search for new molecules, designs and strategies for combating infection caused by this type of microorganism. This review has therefore been aimed at describing the currently available AMPs for combating Gram-negative bacteria, exploring the characteristics of these bacteria’s cell envelop hampering the development of new AMPs, and offers a perspective regarding the challenges for designing new AMPs against Gram-negative bacteria.

Trichoderma-Mediated ZnO Nanoparticles and Their Antibiofilm and Antibacterial Activities

“…Antimicrobial resistance is a major worldwide health concern and one of humanity’s most severe threats today [ 1 ]. Antibiotic resistance has been acquired by certain bacterial strains.…”

An in-silico approach to identify novel antimicrobial peptides against multi-drug resistant Stenotrophomonas maltophilia

“…It permits biased or de novo-free prediction for linear peptides with 5-50 amino acids. When the site of interaction is known in advance, PEPFOLD3 can be used to generate the native-like structure of the protein-peptide interaction [20]The amino acid sequence of the peptides was pasted and submitted for modeling.…”

Atomic-Resolution Structures and Mode of Action of Clinically Relevant Antimicrobial Peptides

“…AMPs are often synthesized as large precursor proteins and are released upon digestion caused by host proteases [17][18][19]. Most AMPs are bequeathed with an impressive broad spectrum of anti-pathogenic activity including Gram-negative and Gram-positive bacteria, fungi, viruses, and parasites [20][21][22]. In addition, activities akin to immunomodulatory, anti-inflammatory, wound healing, and biofilm inhibition/eradication are also known for some of them [20][21][22].…”

“…Most AMPs are bequeathed with an impressive broad spectrum of anti-pathogenic activity including Gram-negative and Gram-positive bacteria, fungi, viruses, and parasites [20][21][22]. In addition, activities akin to immunomodulatory, anti-inflammatory, wound healing, and biofilm inhibition/eradication are also known for some of them [20][21][22]. By contrast to conventional antibiotics, antibacterial cell killing of AMPs largely emanate from the disruption of membrane structures.…”